Osimertinib, an irreversible, orally administered EGFR-TKI, was initially approved by the FDA in 2015 and was intended for use only as an adjuvant therapy after tumor resection in adult NSCLC patients with EGFR exon 19 deletions or exon 21 L858 mutations. The gene discussed is EGFR; the disease is neoplasm.